Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2013 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Other Accumulated Expenses of $40.1 million for Q2 2026, up 44.65% year-over-year from $27.7 million in Q2 2025, and down 51.7% on a QoQ basis from $83.0 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Other Accumulated Expenses for 14 years, with the latest figure at $40.1 million in Q2 2026.
- Other Accumulated Expenses for Q2 2026 came in at $40.1 million, up 44.65% year-over-year; the trailing twelve-month figure through Jun 2026 was $40.1 million (up 44.65% YoY), and the FY2025 annual result was $38.2 million, changed N/A from the prior year.
- Other Accumulated Expenses retreated to $40.1 million in Q2 2026, from $83.0 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $83.0 million in Q1 2026 and troughed at $710000.0 in Q3 2023.
- A 5-year average of $19.2 million and a median of $8.6 million in 2022 frame the typical range for Other Accumulated Expenses.
- The widest annual swing landed in 2023, when Other Accumulated Expenses plunged 91.33%; it then jumped 1647.37% in 2026.
- A 5-year view of Other Accumulated Expenses shows it stood at $16.9 million in 2022, then tumbled by 74.6% to $4.3 million in 2023, then dropped by 15.41% to $3.6 million in 2024, then soared by 954.98% to $38.2 million in 2025, then increased by 4.85% to $40.1 million in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $40.1 million in Q2 2026, $83.0 million in Q1 2026, and $38.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.08 Mn |
| Mar 31, 2026 | 82.97 Mn |
| Dec 31, 2025 | 38.22 Mn |
| Sep 30, 2025 | 26.32 Mn |
| Jun 30, 2025 | 27.71 Mn |
| Mar 31, 2025 | 4.75 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Mar 31, 2024 | 9.55 Mn |
| Dec 31, 2023 | 4.28 Mn |
| Sep 30, 2023 | 710,000.00 |
| Mar 31, 2023 | 7.49 Mn |
| Dec 31, 2022 | 16.86 Mn |
| Sep 30, 2022 | 8.19 Mn |
| Jun 30, 2022 | 8.63 Mn |
| Mar 31, 2022 | 8.06 Mn |
| Dec 31, 2021 | 20.13 Mn |
| Sep 30, 2021 | 6.81 Mn |
| Jun 30, 2021 | 6.32 Mn |
| Mar 31, 2021 | 10.46 Mn |
| Dec 31, 2020 | 9.08 Mn |